{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:55:50Z","timestamp":1780372550763,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008386","name":"Marmara University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p> The association between spondyloarthritis and cardiovascular (CV) diseases is complex with variable outcomes. This study aimed to assess the prevalence rates of CV diseases and to analyze the impact of CV risk factors on CV disease in patients with spondyloarthritis.\u00a0A multi-center cross-sectional study using the BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry) database was performed on patients with spondyloarthritis. Socio-demographic, laboratory, and clinical data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2.\u00a0The primary outcome was the overall group\u2019s prevalence rates of CV disease and CV risk factors. The secondary outcome was the difference in socio-demographic and clinical characteristics between the groups and predictive risk factors for CV disease.\u00a0There were 1457 patients with a mean age of 45.7\u2009\u00b1\u200910.9\u00a0years. The prevalence rate for CV disease was 3% (<jats:italic>n<\/jats:italic>\u2009=\u200944). The distribution of these diseases was coronary artery disease (<jats:italic>n<\/jats:italic>\u2009=\u200942), congestive heart failure (<jats:italic>n<\/jats:italic>\u2009=\u20094), peripheral vascular disorders (<jats:italic>n<\/jats:italic>\u2009=\u20096), and cerebrovascular events (<jats:italic>n<\/jats:italic>\u2009=\u20094). Patients in Group 1 were significantly male (<jats:italic>p<\/jats:italic>\u2009=\u20090.014) and older than those in Group 2 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). There were significantly more patients with hypertension, diabetes mellitus, chronic renal failure, dyslipidemia, and malignancy in Group 1 than in Group 2 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Smoking (36.7%), obesity (24.4%), and hypertension (13.8%) were the most prevalent traditional CV risk factors. Hypertension (HR\u2009=\u20093.147, 95% CI 1.461\u20136.778, <jats:italic>p<\/jats:italic>\u2009=\u20090.003), dyslipidemia (HR\u2009=\u20093.476, 95% CI 1.631\u20137.406, <jats:italic>p<\/jats:italic>\u2009=\u20090.001), and cancer history (HR\u2009=\u20095.852, 95% CI 1.189\u201328.810, <jats:italic>p<\/jats:italic>\u2009=\u20090.030) were the independent predictors for CV disease. A multi-center cross-sectional study using the BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry) database was performed on patients with spondyloarthritis. Socio-demographic, laboratory, and clinical data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2. The primary outcome was the overall group\u2019s prevalence rates of CV disease and CV risk factors. The secondary outcome was the difference in socio-demographic and clinical characteristics between the groups and predictive risk factors for CV disease. There were 1457 patients with a mean age of 45.7\u2009\u00b1\u200910.9\u00a0years. The prevalence rate for CV disease was 3% (<jats:italic>n<\/jats:italic>\u2009=\u200944). The distribution of these diseases was coronary artery disease (<jats:italic>n<\/jats:italic>\u2009=\u200942), congestive heart failure (<jats:italic>n<\/jats:italic>\u2009=\u20094), peripheral vascular disorders (<jats:italic>n<\/jats:italic>\u2009=\u20096), and cerebrovascular events (<jats:italic>n<\/jats:italic>\u2009=\u20094). Patients in Group 1 were significantly male (<jats:italic>p<\/jats:italic>\u2009=\u20090.014) and older than those in Group 2 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). There were significantly more patients with hypertension, diabetes mellitus, chronic renal failure, dyslipidemia, and malignancy in Group 1 than in Group 2 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Smoking (36.7%), obesity (24.4%), and hypertension (13.8%) were the most prevalent traditional CV risk factors. Hypertension (HR\u2009=\u20093.147, 95% CI 1.461\u20136.778, <jats:italic>p<\/jats:italic>\u2009=\u20090.003), dyslipidemia (HR\u2009=\u20093.476, 95% CI 1.631\u20137.406, <jats:italic>p<\/jats:italic>\u2009=\u20090.001), and cancer history (HR\u2009=\u20095.852, 95% CI 1.189\u201328.810, <jats:italic>p<\/jats:italic>\u2009=\u20090.030) were the independent predictors for CV disease. The prevalence rate of CV disease was 3.0% in patients with spondyloarthritis. Hypertension, dyslipidemia, and cancer history were the independent CV risk factors for CV disease in patients with spondyloarthritis.\n<\/jats:p>","DOI":"10.1007\/s00296-023-05523-y","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T14:02:26Z","timestamp":1707228146000},"page":"631-642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cross-sectional analysis of cardiovascular disease and risk factors in patients with spondyloarthritis: a real-life evidence from biostar nationwide registry"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3584-2788","authenticated-orcid":false,"given":"Mehmet Tuncay","family":"Duru\u00f6z","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3008-7007","authenticated-orcid":false,"given":"Hatice","family":"Bodur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3570-3825","authenticated-orcid":false,"given":"\u015eebnem","family":"Ataman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8287-2264","authenticated-orcid":false,"given":"G\u00fclcan","family":"G\u00fcrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3012-2968","authenticated-orcid":false,"given":"\u00d6zg\u00fcr","family":"Akg\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4838-1650","authenticated-orcid":false,"given":"Hasan Fatih","family":"\u00c7ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2728-5934","authenticated-orcid":false,"given":"Erhan","family":"\u00c7apk\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1324-2108","authenticated-orcid":false,"given":"I\u0307lhan","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-3854","authenticated-orcid":false,"given":"Aylin","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-9470","authenticated-orcid":false,"given":"Meltem Alkan","family":"Meliko\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5988-7369","authenticated-orcid":false,"given":"I\u0307lker","family":"Ya\u011fc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8630-9233","authenticated-orcid":false,"given":"Fatma G\u00fcl","family":"Yurdakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-5991","authenticated-orcid":false,"given":"Feride Nur","family":"G\u00f6\u011f\u00fc\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5299-7250","authenticated-orcid":false,"given":"Ayhan","family":"Kamanl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-1586","authenticated-orcid":false,"given":"Remzi","family":"\u00c7evik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6453-8382","authenticated-orcid":false,"given":"Lale","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"issue":"4","key":"5523_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jbspin.2017.07.006","volume":"85","author":"C L\u00f3pez-Medina","year":"2018","unstructured":"L\u00f3pez-Medina C, Jim\u00e9nez-G\u00f3mez Y, Molt\u00f3 A, Schiotis RE, Marzo-Ortega H, van Gaalen FA, Ozgocmen S, Dougados M, Calvo-Guti\u00e9rrez J, Castro-Villegas MC, Collantes-Est\u00e9vez E, Font-Ugalde P, ASAS-COMOSPA Task Force (2018) Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: an ancillary study of the ASAS-COMOSPA project. Jt Bone Spine 85(4):447\u2013453. https:\/\/doi.org\/10.1016\/j.jbspin.2017.07.006","journal-title":"Jt Bone Spine"},{"key":"5523_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211033755","author":"I Ferraz-Amaro","year":"2021","unstructured":"Ferraz-Amaro I, Rueda-Gotor J, Genre F, Corrales A, Blanco R, Portilla V, Gonz\u00e1lez Maz\u00f3n I, Llorca J, Exp\u00f3sito R, Vicente EF, Quevedo-Abeledo JC, Rodr\u00edguez-Lozano C, Ortega-Castro R, Ladehesa-Pineda ML, Fern\u00e1ndez-Carballido C, Mart\u00ednez-Vidal MP, Castro-Corredor D, Anino-Fern\u00e1ndez J, Garc\u00eda Vivar ML, Gal\u00edndez-Agirregoikoa E, Peiteado D, Plasencia-Rodr\u00edguez C, Montes Perez E, Fern\u00e1ndez D\u00edaz C, Casta\u00f1eda S, Gonz\u00e1lez-Gay M\u00c1 (2021) Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720X211033755","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"5523_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.37616\/2212-5043.1258","volume":"33","author":"J Eddarami","year":"2021","unstructured":"Eddarami J, Azzouzi H, Ichchou L (2021) Heart \u0131nvolvement in a moroccan population with spondyloarthritis: a cross-sectional study. J Saudi Heart Assoc 33(2):191\u2013197. https:\/\/doi.org\/10.37616\/2212-5043.1258","journal-title":"J Saudi Heart Assoc"},{"key":"5523_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20982837","author":"ML Ladehesa-Pineda","year":"2020","unstructured":"Ladehesa-Pineda ML, Arias de la Rosa I, L\u00f3pez Medina C, Castro-Villegas MDC, \u00c1balos-Aguilera MDC, Ortega-Castro R, G\u00f3mez-Garc\u00eda I, Segu\u00ed-Azpilcueta P, Jim\u00e9nez-G\u00f3mez Y, Escudero-Contreras A, L\u00f3pez Pedrera C, Barbarroja N, Collantes-Est\u00e9vez E, CASTRO Working Group (2020) Assessment of the relationship between estimated cardiovascular risk and structural damage in patients with axial spondyloarthritis. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720X20982837","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5523_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211032444","author":"SCW Chan","year":"2021","unstructured":"Chan SCW, Teo CK, Li PH, Lau KK, Lau CS, Chung HY (2021) Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720X211032444","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"7","key":"5523_CR6","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.3390\/ijerph19074098","volume":"19","author":"CM Kao","year":"2022","unstructured":"Kao CM, Wang JS, Ho WL, Ko TM, Chen HM, Lin CH, Huang WN, Chen YH, Chen HH (2022) Factors associated with the risk of major adverse cardiovascular events in patients with ankylosing spondylitis: a nationwide, population-based case-control study. Int J Environ Res Public Health 19(7):4098. https:\/\/doi.org\/10.3390\/ijerph19074098","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"5523_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/1744666X.2022.2039630","volume":"18","author":"F Atzeni","year":"2022","unstructured":"Atzeni F, Popa CD, Nucera V, Nurmohamed MT (2022) Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events. Expert Rev Clin Immunol 18(3):233\u2013244. https:\/\/doi.org\/10.1080\/1744666X.2022.2039630","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"5523_CR8","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3899\/jrheum.210909","volume":"49","author":"E Kelty","year":"2022","unstructured":"Kelty E, Ognjenovic M, Raymond WD, Inderjeeth CA, Keen HI, Preen DB, Nossent JC (2022) Mortality rates in patients with ankylosing spondylitis with and without extraarticular manifestations and comorbidities: a retrospective cohort study. J Rheumatol 49(7):688\u2013693. https:\/\/doi.org\/10.3899\/jrheum.210909","journal-title":"J Rheumatol"},{"key":"5523_CR9","doi-asserted-by":"publisher","first-page":"keac210","DOI":"10.1093\/rheumatology\/keac210","volume":"4","author":"AM Kerola","year":"2022","unstructured":"Kerola AM, Kazemi A, Rollefstad S, Lillegraven S, Sexton J, Wibetoe G, Haavardsholm EA, Kvien TK, Semb AG (2022) All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology (Oxford) 4:keac210. https:\/\/doi.org\/10.1093\/rheumatology\/keac210","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"5523_CR10","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s10067-020-05354-3","volume":"40","author":"A S\u00f6dergren","year":"2021","unstructured":"S\u00f6dergren A, Askling J, Bengtsson K, Forsblad-d\u2019Elia H, Jernberg T, Lindstr\u00f6m U, Ljung L, Mantel \u00c4, Jacobsson LTH (2021) Characteristics and outcome of a first acute myocardial infarction in patients with ankylosing spondylitis. Clin Rheumatol 40(4):1321\u20131329. https:\/\/doi.org\/10.1007\/s10067-020-05354-3","journal-title":"Clin Rheumatol"},{"issue":"8","key":"5523_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/medicina56080415","volume":"56","author":"I Ferraz-Amaro","year":"2020","unstructured":"Ferraz-Amaro I, Prieto-Pe\u00f1a D, Palmou-Fontana N, Mart\u00ednez-L\u00f3pez D, de Armas-Rillo L, Garc\u00eda-Dorta A, Atienza-Mateo B, Blanco R, Armesto S, Gonz\u00e1lez-Gay M\u00c1 (2020) The number of traditional cardiovascular risk factors \u0131s \u0131ndependently correlated with disease activity in patients with psoriatic arthritis. Medicina (Kaunas) 56(8):415. https:\/\/doi.org\/10.3390\/medicina56080415","journal-title":"Medicina (Kaunas)"},{"issue":"9","key":"5523_CR12","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/1756-185X.13912","volume":"23","author":"CH Chen","year":"2020","unstructured":"Chen CH, Chen HA, Liu CH, Liao HT, Chou CT, Chen CH (2020) Association of obesity with inflammation, disease severity and cardiovascular risk factors among patients with ankylosing spondylitis. Int J Rheum Dis 23(9):1165\u20131174. https:\/\/doi.org\/10.1111\/1756-185X.13912","journal-title":"Int J Rheum Dis"},{"key":"5523_CR13","doi-asserted-by":"publisher","first-page":"152037","DOI":"10.1016\/j.semarthrit.2022.152037","volume":"55","author":"J Rueda-Gotor","year":"2022","unstructured":"Rueda-Gotor J, Ferraz-Amaro I, Genre F, Gonz\u00e1lez-Maz\u00f3n I, Corrales A, Calvo-Rio V, Portilla V, Llorca J, Exp\u00f3sito R, Hern\u00e1ndez-Hern\u00e1ndez V, Quevedo-Abeledo JC, Rodr\u00edguez-Lozano C, Lopez-Medina C, Ladehesa-Pineda ML, Casta\u00f1eda S, Vicente EF, Fern\u00e1ndez-Carballido C, Mart\u00ednez-Vidal MP, Castro-Corredor D, Anino-Fern\u00e1ndez J, Peiteado D, Plasencia-Rodr\u00edguez C, Garc\u00eda-Vivar ML, Gal\u00edndez-Agirregoikoa E, Montes-Perez E, Fern\u00e1ndez-D\u00edaz C, Blanco R, Gonz\u00e1lez-Gay M\u00c1 (2022) Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients. Semin Arthritis Rheum 55:152037. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152037","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"5523_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.semarthrit.2021.02.003","volume":"51","author":"I Gonz\u00e1lez Maz\u00f3n","year":"2021","unstructured":"Gonz\u00e1lez Maz\u00f3n I, Rueda-Gotor J, Ferraz-Amaro I, Genre F, Corrales A, Calvo Rio V, Palmou Fontana N, Portilla V, Llorca J, Mata C, Hern\u00e1ndez-Hern\u00e1ndez V, Quevedo-Abeledo JC, Rodr\u00edguez-Lozano C, Lopez Medina C, Ladehesa-Pineda ML, Casta\u00f1eda S, Vicente EF, Fern\u00e1ndez-Carballido C, Mart\u00ednez-Vidal MP, Castro-Corredor D, Anino-Fern\u00e1ndez J, Peiteado D, Plasencia-Rodr\u00edguez C, Garc\u00eda-Vivar ML, Gal\u00edndez-Agirregoikoa E, Montes Perez E, Fern\u00e1ndez D\u00edaz C, Blanco R, Gonz\u00e1lez-Gay MA (2021) Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients. Semin Arthritis Rheum 51(2):395\u2013403. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.02.003","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"5523_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/1756-185X.13970","volume":"24","author":"JH Kim","year":"2021","unstructured":"Kim JH, Choi IA (2021) Cardiovascular morbidity and mortality in patients with spondyloarthritis: a meta-analysis. Int J Rheum Dis 24(4):477\u2013486. https:\/\/doi.org\/10.1111\/1756-185X.13970","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"5523_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213317","volume":"78","author":"S Mathieu","year":"2019","unstructured":"Mathieu S, Soubrier M (2019) Cardiovascular events in ankylosing spondylitis: a 2018 meta-analysis. Ann Rheum Dis 78(6):e57. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213317","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5523_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehr205","volume":"33","author":"ZJ Yang","year":"2012","unstructured":"Yang ZJ, Liu J, Ge JP, Chen L, Zhao ZG, Yang WY, China National Diabetes and Metabolic Disorders Study Group (2012) Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007\u20132008 China National Diabetes and Metabolic Disorders Study. Eur Heart J 33(2):213\u2013220. https:\/\/doi.org\/10.1093\/eurheartj\/ehr205","journal-title":"Eur Heart J"},{"issue":"7","key":"5523_CR18","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s10067-022-06145-8","volume":"41","author":"H Bodur","year":"2022","unstructured":"Bodur H, Yurdakul FG, Ataman S, Cay HF, Gurer G, Capkin E, Sezer \u0130, Duruoz MT, Melikoglu MA, Rezvani A, Yagci I, Gogus F, Kamanli A, Akgul O, Cevik R (2022) Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry. Clin Rheumatol 41(7):2053\u20132063. https:\/\/doi.org\/10.1007\/s10067-022-06145-8","journal-title":"Clin Rheumatol"},{"issue":"2","key":"5523_CR19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3899\/jrheum.181415","volume":"47","author":"G Fitzgerald","year":"2020","unstructured":"Fitzgerald G, Gallagher P, O\u2019Shea FD (2020) multimorbidity in axial spondyloarthropathy and its association with disease outcomes: results from the Ankylosing Spondylitis Registry of Ireland Cohort. J Rheumatol 47(2):218\u2013226. https:\/\/doi.org\/10.3899\/jrheum.181415","journal-title":"J Rheumatol"},{"issue":"11","key":"5523_CR20","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s00296-020-04680-8","volume":"40","author":"O Akgul","year":"2020","unstructured":"Akgul O, Bodur H, Ataman S, Yurdakul FG, Capkin E, Gurer G, Sezer I, Duruoz MT, Melikoglu MA, Cay HF, Rezvani A, Yagci I, Gogus F, Kamanli A, Cevik R (2020) Clinical performance of ASAS Health Index in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: real-world evidence from Multicenter Nationwide Registry. Rheumatol Int 40(11):1793\u20131801. https:\/\/doi.org\/10.1007\/s00296-020-04680-8","journal-title":"Rheumatol Int"},{"issue":"2","key":"5523_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.5152\/eurjrheum.2022.21060","volume":"9","author":"F \u00d6nen","year":"2022","unstructured":"\u00d6nen F, Can G, \u00c7apar S, Dalk\u0131l\u0131\u00e7 E, Pehlivan Y, \u015eenel S, Akar S, Koca SS, Tufan A, Yaz\u0131c\u0131 A, Y\u0131lmaz S, \u0130nan\u00e7 N, Sar\u0131 \u0130, Birlik M, Solmaz D, Cefle A, \u00d6zt\u00fcrk MA, Yolba\u015f S, Krogh NS, Y\u0131lmaz N, Erten \u015e, Bes C, G\u00fcnd\u00fcz \u00d6S, G\u00f6ker B, Haznedaro\u011flu S, Yavuz \u015e, Yildirim \u00c7etin G, Y\u0131ld\u0131z F, Direskeneli H, Akko\u00e7 N (2022) A real-life analysis of patients with rheumatologic diseases on biological treatments: data from TURKBIO Registry. Eur J Rheumatol 9(2):82\u201387. https:\/\/doi.org\/10.5152\/eurjrheum.2022.21060","journal-title":"Eur J Rheumatol"},{"issue":"6","key":"5523_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, S\u00f8rensen IJ, Ozgocmen S, Roussou E, Valle-O\u00f1ate R, Weber U, Wei J, Sieper J (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777\u2013783. https:\/\/doi.org\/10.1136\/ard.2009.108233. (Erratum in: Ann Rheum Dis. 2019 Jun; 78(6): e59)","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"5523_CR23","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286\u20132291","journal-title":"J Rheumatol"},{"issue":"12","key":"5523_CR24","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O\u2019Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281\u20132285","journal-title":"J Rheumatol"},{"issue":"11","key":"5523_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215960","volume":"79","author":"RSG Gon\u00e7alves","year":"2020","unstructured":"Gon\u00e7alves RSG, de Almeida Martins LM, de Ataide MH, Dantas AT, Duarte ALBP (2020) DAPSA versus cDAPSA: do we need to use CRP? Ann Rheum Dis 79(11):e142. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215960","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5523_CR26","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/13696998.2019.1627362","volume":"22","author":"LS Matza","year":"2019","unstructured":"Matza LS, Brazier JE, Stewart KD, Pinto L, Bender RH, Kircik L, Jordan J, Kim KJ, Mutebi A, Viswanathan HN, Menter A (2019) Developing a preference-based utility scoring algorithm for the psoriasis area severity index (PASI). J Med Econ 22(9):936\u2013944. https:\/\/doi.org\/10.1080\/13696998.2019.1627362","journal-title":"J Med Econ"},{"issue":"1","key":"5523_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46497\/ArchRheumatol.2021.7874","volume":"36","author":"Y Keskin","year":"2020","unstructured":"Keskin Y, Nas K, Kili\u00e7 E, Sargin B, Acer Kasman S, Alkan H, \u015eahin N, Cengiz G, Cuzdan N, Albayrak Gezer \u0130, Keskin D, M\u00fclko\u011flu C, Resorlu H, Ataman \u015e, Bal A, Duruoz MT, K\u00fc\u00e7\u00fckakkas O, Yurdakul OV, Alkan Meliko\u011flu M, Aydin Y, Ayhan FF, Bodur H, \u00c7ali\u015f M, \u00c7apkin E, Devrimsel G, G\u00f6k K, Hizmetli S, Kamanli A, Ecesoy H, Kutluk \u00d6, \u015een N, \u015eendur \u00d6F, Tekeo\u011flu \u0130, Tolu S, Toprak M, Tuncer T (2020) Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. Arch Rheumatol 36(1):1\u20139. https:\/\/doi.org\/10.46497\/ArchRheumatol.2021.7874","journal-title":"Arch Rheumatol"},{"issue":"4","key":"5523_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.reuma.2014.07.008","volume":"11","author":"S Moyano","year":"2015","unstructured":"Moyano S, Kilstein JG, Alegre de Miguel C (2015) New diagnostic criteria for fibromyalgia: here to stay? Reumatol Clin 11(4):210\u2013214. https:\/\/doi.org\/10.1016\/j.reuma.2014.07.008","journal-title":"Reumatol Clin"},{"issue":"21","key":"5523_CR29","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1080\/09638288.2022.2127931","volume":"45","author":"E Latifoglou","year":"2023","unstructured":"Latifoglou E, \u00c7\u0131nar E, Tan\u0131g\u00f6r G, On AY (2023) Coexistence of fibromyalgia and post-polio syndrome in persons with prior poliomyelitis in Turkey: the relations with symptoms, polio-related impairments, and quality of life. Disabil Rehabil 45(21):3511\u20133518. https:\/\/doi.org\/10.1080\/09638288.2022.2127931","journal-title":"Disabil Rehabil"},{"key":"5523_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.909760","volume":"13","author":"DM Schwartz","year":"2022","unstructured":"Schwartz DM, Parel P, Li H, Sorokin AV, Berg AR, Chen M, Dey A, Hong CG, Playford M, Sylvester M, Teague H, Siegel E, Mehta NN (2022) PET\/CT-based characterization of 18F-FDG uptake in various tissues reveals novel potential contributions to coronary artery disease in psoriatic arthritis. Front Immunol 13:909760. https:\/\/doi.org\/10.3389\/fimmu.2022.909760","journal-title":"Front Immunol"},{"issue":"2","key":"5523_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001568","volume":"7","author":"AJ Landgren","year":"2021","unstructured":"Landgren AJ, Dehlin M, Jacobsson L, Bergsten U, Klingberg E (2021) Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden. RMD Open 7(2):e001568. https:\/\/doi.org\/10.1136\/rmdopen-2021-001568","journal-title":"RMD Open"},{"issue":"6","key":"5523_CR32","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1093\/rheumatology\/keaa737","volume":"60","author":"MA Mart\u00edn-Mart\u00ednez","year":"2021","unstructured":"Mart\u00edn-Mart\u00ednez MA, Casta\u00f1eda S, S\u00e1nchez-Alonso F, Garc\u00eda-G\u00f3mez C, Gonz\u00e1lez-Juanatey C, S\u00e1nchez-Costa JT, Belmonte-L\u00f3pez MA, Tornero-Molina J, Santos-Rey J, S\u00e1nchez Gonz\u00e1lez CO, Quesada E, Moreno-Gil MP, Cobo-Ib\u00e1\u00f1ez T, Pinto-Tasnde JA, Bab\u00edo-Herr\u00e1ez J, Bonilla G, Juan-Mas A, Manero-Ruiz FJ, Romera-Baur\u00e9s M, Bachiller-Corral J, Chamizo-Carmona E, Uriarte-Ecenarro M, Barbadillo C, Fern\u00e1ndez-Carballido C, Aurrecoechea E, M\u00f6ller-Parrera I, Llorca J, Gonz\u00e1lez-Gay MA, CARMA Project Collaborative Group (2021) Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up. Rheumatology (Oxford) 60(6):2906\u20132915. https:\/\/doi.org\/10.1093\/rheumatology\/keaa737","journal-title":"Rheumatology (Oxford)"},{"key":"5523_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221122401","author":"LH Shi","year":"2022","unstructured":"Shi LH, Lam SH, So H, Li EK, Li TK, Szeto CC, Tam LS (2022) High inflammatory burden predicts cardiovascular events in patients with axial spondyloarthritis: a long-term follow-up study. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720X221122401","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5523_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.786776","volume":"9","author":"V Yagensky","year":"2022","unstructured":"Yagensky V, Schirmer M (2022) Cardiovascular risks and risk stratification in inflammatory joint diseases: a cross-sectional study. Front Med (Lausanne) 9:786776. https:\/\/doi.org\/10.3389\/fmed.2022.786776","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"5523_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13075-017-1358-1","volume":"19","author":"G Wibetoe","year":"2017","unstructured":"Wibetoe G, Ikdahl E, Rollefstad S, Olsen IC, Bergsmark K, Kvien TK, Salberg A, Soldal DM, Bakland G, Lexberg \u00c5, Fevang BT, Gulseth HC, Haugeberg G, Semb AG (2017) Cardiovascular disease risk profiles in inflammatory joint disease entities. Arthritis Res Ther 19(1):153. https:\/\/doi.org\/10.1186\/s13075-017-1358-1","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"5523_CR36","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.semarthrit.2014.12.002","volume":"44","author":"S Casta\u00f1eda","year":"2015","unstructured":"Casta\u00f1eda S, Mart\u00edn-Mart\u00ednez MA, Gonz\u00e1lez-Juanatey C, Llorca J, Garc\u00eda-Y\u00e9benes MJ, P\u00e9rez-Vicente S, S\u00e1nchez-Costa JT, D\u00edaz-Gonzalez F, Gonz\u00e1lez-Gay MA (2015) Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: baseline data of the CARMA Project. Semin Arthritis Rheum 44(6):618\u2013626. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.12.002. (Erratum in: Semin Arthritis Rheum. 2015 Oct; 45(2):e7\u20138)","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"5523_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.811664","volume":"11","author":"YF Lai","year":"2022","unstructured":"Lai YF, Lin TY, Chien WC, Sun CA, Chung CH, Chen YH, Chen JT, Chen CL (2022) Uveitis as a risk factor for developing acute myocardial infarction in ankylosing spondylitis: a national population-based longitudinal cohort study. Front Immunol 11(12):811664. https:\/\/doi.org\/10.3389\/fimmu.2021.811664","journal-title":"Front Immunol"},{"issue":"13","key":"5523_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.890543","volume":"10","author":"KM Feng","year":"2022","unstructured":"Feng KM, Chien WC, Chen YH, Sun CA, Chung CH, Chen JT, Chen CL (2022) Increased risk of acute coronary syndrome in ankylosing spondylitis patients with uveitis: a population-based cohort study. Front Immunol 10(13):890543. https:\/\/doi.org\/10.3389\/fimmu.2022.890543","journal-title":"Front Immunol"},{"issue":"3","key":"5523_CR39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3899\/jrheum.200188","volume":"48","author":"JW Liew","year":"2021","unstructured":"Liew JW, Reveille JD, Castillo M, Sawhney H, Naovarat BS, Heckbert SR, Gensler LS (2021) Cardiovascular risk scores in axial spondyloarthritis versus the general population: a cross-sectional study. J Rheumatol 48(3):361\u2013366. https:\/\/doi.org\/10.3899\/jrheum.200188","journal-title":"J Rheumatol"},{"issue":"2","key":"5523_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.semarthrit.2012.02.008","volume":"42","author":"S Brophy","year":"2012","unstructured":"Brophy S, Cooksey R, Atkinson M, Zhou SM, Husain MJ, Macey S, Rahman MA, Siebert S (2012) No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis\u2014a retrospective cohort study using routine data. Semin Arthritis Rheum 42(2):140\u2013145. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.02.008","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"5523_CR41","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1136\/annrheumdis-2016-210275","volume":"76","author":"O Schieir","year":"2017","unstructured":"Schieir O, Tosevski C, Glazier RH, Hogg-Johnson S, Badley EM (2017) Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann Rheum Dis 76(8):1396\u20131404. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210275","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5523_CR42","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40744-020-00248-x","volume":"7","author":"P Karmacharya","year":"2020","unstructured":"Karmacharya P, Shahukhal R, Crowson CS, Murad MH, Davis JM 3rd, Shrestha P, Bekele D, Wright K, Chakradhar R, Dubreuil M (2020) Effects of therapies on cardiovascular events in ankylosing spondylitis: a systematic review and meta-analysis. Rheumatol Ther 7(4):993\u20131009. https:\/\/doi.org\/10.1007\/s40744-020-00248-x","journal-title":"Rheumatol Ther"},{"issue":"4","key":"5523_CR43","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/rheumatology\/keaa683","volume":"60","author":"R Persson","year":"2021","unstructured":"Persson R, Hagberg KW, Qian Y, Vasilakis-Scaramozza C, Jick S (2021) The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids. Rheumatology (Oxford) 60(4):1926\u20131931. https:\/\/doi.org\/10.1093\/rheumatology\/keaa683","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"5523_CR44","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s10067-022-06473-9","volume":"42","author":"H Bodur","year":"2023","unstructured":"Bodur H (2023) Cardiovascular comorbidities in spondyloarthritis. Clin Rheumatol 42(10):2611\u20132620. https:\/\/doi.org\/10.1007\/s10067-022-06473-9","journal-title":"Clin Rheumatol"},{"key":"5523_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.782150","volume":"8","author":"E Toussirot","year":"2021","unstructured":"Toussirot E (2021) The risk of cardiovascular diseases in axial spondyloarthritis. Current insights. Front Med (Lausanne) 8:782150. https:\/\/doi.org\/10.3389\/fmed.2021.782150","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"5523_CR46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40744-022-00434-z","volume":"9","author":"JF Merola","year":"2022","unstructured":"Merola JF, McInnes IB, Deodhar AA, Dey AK, Adamstein NH, Quebe-Fehling E, Aassi M, Peine M, Mehta NN (2022) Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications. Rheumatol Ther 9(3):935\u2013955. https:\/\/doi.org\/10.1007\/s40744-022-00434-z","journal-title":"Rheumatol Ther"},{"issue":"1","key":"5523_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-022-02836-4","volume":"24","author":"OC Kwon","year":"2022","unstructured":"Kwon OC, Park MC (2022) Effect of tumor necrosis factor inhibitors on risk of cardiovascular disease in patients with axial spondyloarthritis. Arthritis Res Ther 24(1):141. https:\/\/doi.org\/10.1186\/s13075-022-02836-4","journal-title":"Arthritis Res Ther"},{"issue":"10214","key":"5523_CR48","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J (2019) Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet 394(10214):2108\u20132117. https:\/\/doi.org\/10.1016\/S0140-6736(19)32534-6","journal-title":"Lancet"},{"issue":"3","key":"5523_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001838","volume":"7","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Kato K, Magrey M, Merola JF, Kishimoto M, Pacheco-Tena C, Haaland D, Chen L, Duan Y, Zueger P, Liu J, Lippe R, Pangan AL, Behrens F (2021) Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open 7(3):e001838. https:\/\/doi.org\/10.1136\/rmdopen-2021-001838. (Erratum in: RMD Open. 2021 Nov; 7(3))","journal-title":"RMD Open"},{"issue":"10349","key":"5523_CR50","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Blanco R, Duan Y, Li Y, Pangan AL, Wung P, Song IH (2022) Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 400(10349):369\u2013379. https:\/\/doi.org\/10.1016\/S0140-6736(22)01212-0","journal-title":"Lancet"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05523-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05523-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05523-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T21:36:57Z","timestamp":1709933817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05523-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["5523"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05523-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"14 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all subjects before enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}